WHO Sounds Warning Over Critical Lack of Weight-Loss Medications
Under a tenth of people who could benefit from weight-loss injections including Wegovy can access them, states the global health agency as it issues its inaugural advice on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging broader and more equitable access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be addressed with comprehensive and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major hurdles to widespread availability to the jabs that can aid individuals in losing significant body mass, notes the organization.
Skinny Jab Shortage
Even under the present most optimistic case, the supply of these medications could only cover about 100 million people – less than 10% of the global need, as stated by the WHO.
The guideline urges nations and manufacturers to expand availability, by strategies such as patent sharing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.
The Way Obesity Drugs Function
These medications replicate a biological compound to slow digestion, reduce hunger and boost the sense of being full so individuals consume fewer calories.
Individuals commonly begin shedding pounds after several weeks of starting on the weekly injections.
Research points to patients may put most of the weight back on a year later of discontinuing the drug, as their usual appetite come back.
Being above a healthy weight increases your risk for developing health problems, like diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, per the health agency.
